Dotti KF - Search Results

1

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Martinetti A, et al. Among authors: dotti kf. Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753. Cancers (Basel). 2014. PMID: 25256831 Free PMC article.

2

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

Pietrantonio F, Biondani P, Pellegrinelli A, Marchianò A, Dotti KF, Buzzoni R, Di Bartolomeo M. Pietrantonio F, et al. Among authors: dotti kf. Med Oncol. 2012 Dec;29(4):2838-41. doi: 10.1007/s12032-011-0132-5. Epub 2012 Jan 21. Med Oncol. 2012. PMID: 22271433

3

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.

Di Bartolomeo M, Ciarlo A, Bertolini A, Barni S, Verusio C, Aitini E, Pietrantonio F, Iacovelli R, Dotti KF, Maggi C, Perrone F, Bajetta E. Di Bartolomeo M, et al. Among authors: dotti kf. Eur J Cancer. 2015 Mar;51(4):473-481. doi: 10.1016/j.ejca.2014.12.020. Epub 2015 Jan 27. Eur J Cancer. 2015. PMID: 25637137 Clinical Trial.

4

Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.

Bajetta E, Verzoni E, Ferrario E, Dotti K, Gevorgyan A, Celio L. Bajetta E, et al. Tumori. 2009 Jan-Feb;95(1):43-7. doi: 10.1177/030089160909500108. Tumori. 2009. PMID: 19366055 Clinical Trial.

5

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

Bajetta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Dotti KF, Mariani L, Bajetta R, Gevorgyan A, Venturino P, Galassi M. Bajetta E, et al. Among authors: dotti kf. Cancer Chemother Pharmacol. 2009 Jun;64(1):67-72. doi: 10.1007/s00280-008-0852-1. Epub 2008 Oct 21. Cancer Chemother Pharmacol. 2009. PMID: 18936940 Clinical Trial.

6

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group. Di Bartolomeo M, et al. Among authors: dotti kf. Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3. Target Oncol. 2014. PMID: 23821376 Clinical Trial.

7

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.

Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Pietrantonio F, et al. Among authors: dotti kf. Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2. Target Oncol. 2016. PMID: 26538496

8

Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.

Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M. Bajetta E, et al. Among authors: dotti kf. Am J Clin Oncol. 2014 Dec;37(6):545-9. doi: 10.1097/COC.0b013e31827ecd1d. Am J Clin Oncol. 2014. PMID: 23428953 Clinical Trial.

9

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study.

Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C, Morelli D, Dotti K, Fiordoliva I, Rinaldi S, Gavazzi C, Pietrantonio F, Platania M, de Braud F. Fucà G, et al. Sci Rep. 2019 Sep 10;9(1):12993. doi: 10.1038/s41598-019-49601-3. Sci Rep. 2019. PMID: 31506579 Free PMC article.

10

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.

Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S. Bajetta E, et al. Ann Oncol. 2007 Nov;18(11):1810-6. doi: 10.1093/annonc/mdm347. Epub 2007 Sep 6. Ann Oncol. 2007. PMID: 17823385 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters